- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06287489
Effects of Mediterranean Diet on Subjective Cognitive Decline
Effects of Mediterranean Diet on Physical and Cognitive Functions in Community-dwelling Older People With Subjective Cognitive Decline - a Randomized Controlled Cross-over Trial
Research Questions:
- Due to the fact that most participants in past clinical trials on the Mediterranean diet were cognitively healthy individuals, and while the observed effects were significant, they were not particularly substantial, does the Mediterranean diet have similarly significant and more pronounced effects on both physical and cognitive functions in older adults with subjective cognitive decline (SCD)?
- What is the mechanism behind the effects of the Mediterranean diet on physical or/and cognitive function? Is it through vascular protection or improvements in brain structure/brain network function?
Research Objective:
Conduct a cross-over randomized controlled trial to investigate the effects of a three-month Mediterranean diet on the physical and cognitive functions of older adults with subjective cognitive decline (SCD) in the community. Utilize brain MRI and circulatory biomarkers measurements to elucidate the underlying mechanisms.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research Questions:
- Due to the fact that most participants in past clinical trials on the Mediterranean diet were cognitively healthy individuals, and while the observed effects were significant, they were not particularly substantial, does the Mediterranean diet have similarly significant and more pronounced effects on both physical and cognitive functions in older adults with subjective cognitive decline (SCD)?
- What is the mechanism behind the effects of the Mediterranean diet on physical or/and cognitive function? Is it through vascular protection or improvements in brain structure/brain network function?
Research Objective:
Conduct a randomized controlled trial to investigate the effects of a three-month Mediterranean diet on the physical and cognitive functions of older adults with subjective cognitive decline (SCD) in the community. Utilize brain MRI to elucidate the underlying mechanisms.
Participants inclusion criteria:
SCD-plus subjects must fullfill the following five criteria
- Subjective memory decline without impairment in other cognitive domains (MMSE > 26; MMSE > 14 for those with less than six years of education).
- Onset of subjective cognitive decline within the past 5 years.
- Age at the onset of subjective cognitive decline is greater than 60 years.
- Concern and preoccupation with the decline in memory.
Perceived functional decline relative to peers and meet one of the following three criteria:
- Caregiver perceives cognitive decline.
- Carries the APOE ε4 genotype.
- Clinical evidence of preclinical Alzheimer's disease biomarkers.
Participants exclusion criteria:
- Cases unable to comply with or accept the dietary intervention, including individuals with dietary restrictions such as vegetarianism, lactose intolerance, or potential food allergies.
- Walking speed ≤ 0.3 meters/second.
Any significant medical conditions affecting physical and cognitive functions, including:
- Limb fracture within the past six months.
- Severe arthritis within the past six months.
- Neurological and psychiatric disorders as determined by the principal investigator (e.g., stroke, Parkinson's disease, peripheral neuropathy, mental disorders).
- Intermittent claudication due to peripheral arterial disease.
- Chronic kidney disease (eGFR <30 ml/min/1.73m2) and individuals undergoing dialysis.
- Poorly controlled cardiovascular diseases as determined by the principal investigator.
- Poorly controlled malignant tumors as determined by the principal investigator.
- Severe visual and hearing impairments preventing the completion of assessments and tests.
- Participants who have undergone hormone therapy in the three months preceding the trial or are expected to undergo hormone therapy during the trial.
Study Design or Implementation:
This study is a cross-over (three month of Mediterranean diet phase "M" and three month of regular diet phase "R") randomized controlled trial with a duration of six to seven months (seven month for MR group with an additional one-month washout period). During the study period, participants in the M phase will receive a daily portion of a Mediterranean diet designed by a nutritionist. Regular Mediterranean diet education and reviews will be conducted to ensure that the Mediterranean Diet Score System (MDSS) reaches a score of ≥10. The R phase will follow a self-selected diet, and the MDSS during then will also be assessed.
Eligible participants will be randomly assigned to two groups with different diet sequences (MR or RM group) in a 1:1 ratio. T0 measurements will be conducted, including a basic information questionnaire, blood biomarker sampling for Alzheimer's disease, and the initial assessment of physical and cognitive functions. Dietary assessments and education will be conducted before entering the dietary intervention group and at one week, two weeks, one month, two months, and three months after entering each phase. Other measurements, including blood pressure, heart rate, height and weight measurements, blood tests, and brain MRI, will be performed at T1 and T2 (end of each diet phase).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chih-Ping Chung, MD PhD
- Phone Number: +886-2-918155976
- Email: pin324pin324@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Chih-Ping Chung, MD PhD
- Phone Number: +886-2-918155976
- Email: pin324pin324@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjective cognitive decline (SCD)-plus subjects, individuals must meet five criteria:
- Subjective memory decline without impairment in other cognitive domains (MMSE > 26; MMSE > 14 for <6 years of education).
- Onset of subjective cognitive decline within the past 5 years.
- Age at the onset of subjective cognitive decline is >60 years.
- Concern and preoccupation with memory decline.
- Perceived functional decline relative to peers and meet one of three criteria: a. Caregiver perceives cognitive decline; b. Carries APOE ε4 genotype; c. Clinical evidence of preclinical Alzheimer's disease biomarkers.
Exclusion Criteria:
Exclude individuals who:
- Cannot comply with or accept the dietary intervention (e.g., dietary restrictions, vegetarianism, lactose intolerance).
- Have walking speed ≤ 0.3 meters/second.
- Have significant medical conditions affecting physical and cognitive functions.
- Have chronic kidney disease (eGFR <30 ml/min/1.73m2) or undergo dialysis.
- Experience poorly controlled cardiovascular diseases or malignant tumors.
- Have severe visual and hearing impairments preventing assessments.
- Have undergone hormone therapy in the preceding three months or are expected to during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Mediterranean diet phase followed by regular diet phase
Three-month of M phase, one month of washout and three month of R phase
|
Mediterranean diet for three month
regular diet
|
Other: Regular diet phase followed by Mediterranean diet phase
Three-month of R phase followed by three month of M phase
|
Mediterranean diet for three month
regular diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive functional change
Time Frame: Three month of allocated diet phase
|
Subjective and objective cognitive functional measurements (MMSE and comprehensive neuropsychological tests for verbal memory, attention, visuospatial function, executive function, and language)
|
Three month of allocated diet phase
|
Physical function 1 - gait speed change
Time Frame: Three month of allocated diet phase
|
Gait speed measurements
|
Three month of allocated diet phase
|
Physical function 2 - handgrip strength change
Time Frame: Three month of allocated diet phase
|
Handgrip strength measurements
|
Three month of allocated diet phase
|
Physical function 3 - stand from chair speed change
Time Frame: Three month of allocated diet phase
|
Five times of stand from chair speed measurements
|
Three month of allocated diet phase
|
Brain MRI structural change - total and regional voxel-based brain parenchymal features change
Time Frame: Three month of allocated diet phase
|
Brain gray matter/white matter volumes and diffusion tensor imaging measurements
|
Three month of allocated diet phase
|
Brain MRI functional change - total and regional voxel-based brain functional features change
Time Frame: Three month of allocated diet phase
|
Resting functional MRI signal analsyes
|
Three month of allocated diet phase
|
Brain MRI neurovascular lesion change - small vessel disease markers
Time Frame: Three month of allocated diet phase
|
white matter hyperintensities, lacune and cerebral microbleeds assessments
|
Three month of allocated diet phase
|
Brain MRI neurovascular structural change - microvascular density
Time Frame: Three month of allocated diet phase
|
arteriolar and venular densities
|
Three month of allocated diet phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AD circulatory biomarkers
Time Frame: Three month of allocated diet phase
|
Amyloid beta 40/42, p-tau-217, NfL, TDP43,ASC level changes
|
Three month of allocated diet phase
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Chih-Ping Chung, MD PhD, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- No.:2023-08-010ACF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subjective Cognitive Decline
-
Beijing Hospital of Traditional Chinese MedicineUnknownSubjective Cognitive Decline | Subjective Cognitive ComplaintChina
-
University of WaterlooUniversity of Ottawa; Baycrest; Université de MontréalRecruiting
-
Vanderbilt University Medical CenterNot yet recruiting
-
Indiana UniversityNational Institute on Aging (NIA)CompletedSubjective Cognitive DeclineUnited States
-
Centre de Recherche de l'Institut Universitaire...Canadian Institutes of Health Research (CIHR); Rotman Research Institute at...Active, not recruitingSubjective Cognitive DeclineCanada
-
BaycrestCompletedSubjective Cognitive DeclineCanada
-
BaycrestCompletedSubjective Cognitive DeclineCanada
-
Evidation HealthNeurotrackCompleted
-
Fundacion Clinic per a la Recerca BiomédicaUnknownSubjective Cognitive Decline
-
Vanderbilt University Medical CenterRecruiting
Clinical Trials on Mediterranean diet
-
Purdue UniversityMushroom CouncilCompleted
-
University of East AngliaNewcastle UniversityRecruitingDepression, AnxietyUnited Kingdom
-
University of California, IrvineCompletedPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Disorder | Myeloproliferative SyndromeUnited States
-
Gangnam Severance HospitalUnknown
-
Federico II UniversityCompletedMediterranean Diet | Neuroendocrine Tumours (NETs)Italy
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
University of California, DavisCompletedInflammation | Diet Modification | HDLUnited States
-
michal rollUnknown
-
University of Campania "Luigi Vanvitelli"CompletedType 2 Diabetes MellitusItaly
-
Azienda Ospedaliero-Universitaria CareggiCompleted